Ensign Peak Advisors’s Pacific Biosciences PACB Stock Holding History

Ensign Peak Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-98,112	Closed	-$368K	–	1732
2024 Q1	$368K	Buy	98,112 +4,662	+5%	+$27.3K	﹤0.01%	1673
2023 Q4	$917K	Buy	93,450 +12,100	+15%	+$99K	﹤0.01%	1435
2023 Q3	$679K	Hold	81,350	–	–	﹤0.01%	1458
2023 Q2	$1.08M	Hold	81,350	–	–	﹤0.01%	1188
2023 Q1	$942K	Hold	81,350	–	–	﹤0.01%	1287
2022 Q4	$665K	Buy	81,350 +36,200	+80%	+$312K	﹤0.01%	1494
2022 Q3	$262K	Hold	45,150	–	–	﹤0.01%	1769
2022 Q2	$200K	Hold	45,150	–	–	﹤0.01%	1790
2022 Q1	$411K	Hold	45,150	–	–	﹤0.01%	1635
2021 Q4	$924K	Buy	+45,150	New	+$1.09M	﹤0.01%	1339

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's PACB Position: Q2 2024 in Review

Ensign Peak Advisors sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 98,112 shares — an estimated $368K sold.

Ensign Peak Advisors first reported a position in PACB in Q4 2021 and held it in 10 quarters. The position peaked at $1.08M in Q2 2023. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

Ensign Peak Advisors reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
Ensign Peak Advisors sold 98,112 Pacific Biosciences shares in Q2 2024, an estimated $368K.
Ensign Peak Advisors first reported a position in Pacific Biosciences in Q4 2021 and held it in 10 quarters.
Ensign Peak Advisors's Pacific Biosciences position peaked at $1.08M in Q2 2023.
228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Ensign Peak Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.